Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Diabetes: Do smartphones fit the bill for the next mobile artificial pancreas?
Modern smartphones have the chops to handle diabetes monitoring and management, making them a potentially alluring platform from which to build an artificial pancreas.
2. FDA slaps Nova’s glucose test strip recall with a Class I label
The FDA says Nova Biomedical’s glucose test strip recall is a Class I risk, representing the most significant potential danger to patients.
1. Jury slaps Bard with $2M in damages in Avaulta pelvic mesh bellwether
A federal jury hits C.R. Bard with a $2 million judgment after finding its Avaulta pelvic mesh defective, ruling that Bard failed to warn about problems with the product.